Research progress and prognostic significance of EZH2 in acute myeloid leukemia
10.3969/j.issn.1000-8179.2016.16.518
- VernacularTitle:EZH2在急性髓系白血病病程中的表达和对预后判断的意义研究
- Author:
Jian SUN
;
Xiaobo WANG
;
Qi ZHANG
;
Lijun MU
- Publication Type:Journal Article
- Keywords:
DNMT1;
EZH2;
AML;
correlation
- From:
Chinese Journal of Clinical Oncology
2016;43(16):727-730
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between DNA methyltransferase (DNMT1) and EZH2 gene expression levels and their clinical significance in patients with acute myeloid leukemia (AML). Methods:The mRNA expression levels of DNMT1 and EZH2 in 50 AML cases and 30 healthy controls were quantified through real-time PCR. The relationship among DNA methyltransferase (DNMT1) and EZH2, clinicopathological factors, and prognosis was analyzed. Results:The mRNA expression of DNMT1 in the AML cases (2.72 ± 0.73) was significantly higher than that in the healthy controls (0.89 ± 0.27) (P<0.01). The mRNA expression of EZH2 in the AML cases (4.39±1.06) was also significantly higher than that in the healthy controls (1.87±0.33) (P<0.01). The expression of DNMT1 was positive-ly associated with that of EZH2 (r=0.51, P=0.002). The expression of DNMT1 was also associated with PB%and WBC≥50 × 109/L (P<0.05). The overall survival of the group with a high-mRNA-expressing DNMT1 was 15 months (95%CI=9-19 months). This period was significantly shorter than that of the group with low-mRNA-expressing DNMT1 (32 months, 95%CI=27-40 months;P=0.006). Conclu-sion:DNMT1 and EZH2 expression levels were downregulated. These levels were associated with poor AML prognosis. The expression of DNMT1 was also positively associated with that of EZH2.
